Prostate Cancer & BPHArchives
Aquablation for dual burden disease - BPH and chronic prostatitis/chronic pelvic pain syndrome: a single-center prospective pilot study
Prostate Cancer & BPH 1 min.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounts for approximately 90-95% of prostatitis cases and is defined by pelvic pain or discomfort persisting for at least three of the preceding six months in the absence of identifiable infection. Despite its high prevalence, management remains...
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report
Prostate Cancer & BPH 1 min.
Prostate-specific membrane antigen-direct radioligand therapy (PSMA RLT) is primarily used to treat castration-resistant metastatic prostate cancer (PCa) after prior treatment options have been exhausted. Occasionally, other tumor entities, such as parotid carcinoma in this case, also express prostate-specific...
Feasibility of deep learning-accelerated ultrafast T1-weighted VIBE Dixon imaging of the pelvis for screening of metastases in prostate MRI
Prostate Cancer & BPH 1 min.
This study aims to assess the image quality and perceived diagnostic confidence of research deep learning (DL)-accelerated T1-weighted "volumetric interpolated breath‑hold examination" (VIBE) Dixon sequences compared to conventional T1-weighted VIBE Dixon sequences for the screening of pelvic metastases...
The role of prostatic artery embolization in the management of benign prostatic enlargement in patients with chronic liver disease: a prospective single-center clinical trial
Prostate Cancer & BPH 1 min.
To evaluate the efficacy and safety of prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH) in patients with chronic liver disease, with subgroup analysis according to Child-Pugh classification. Materials and methods: This prospective single-center clinical study enrolled thirty-four...
Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer
Prostate Cancer & BPH 1 min.
Fanconi anemia complementation group D2 (FANCD2) is a key component of DNA damage repair and has emerged as a potential cancer therapy target. Its role in enzalutamide (ENZ) resistance in prostate cancer remains unclear. Methods: FANCD2 expression was examined in prostate cancer cells. Gain- and loss-of-function...
